Evidence map›Paper›PMID 37593443›Full record

ArticleFrontiers in pediatrics2023

Dyskeratosis congenita: natural history of the disease through the study of a cohort of patients diagnosed in childhood.

M L Uria-Oficialdegui, S Navarro, L Murillo-Sanjuan, C Rodriguez-Vigil, M I Benitez-Carbante, C Blazquez-Goñi, J A Salinas, C Diaz-de-Heredia

Abstract read
In one paragraph

Article in Frontiers in pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

M L Uria-OficialdeguiPediatric Hematology and Oncology Division, Hospital Universitari Vall d´Hebron, Barcelona, Spain.
S NavarroPediatric Division, Hospital Universitario SonEspases, Palma de Mallorca, Spain.
L Murillo-SanjuanPediatric Hematology and Oncology Division, Hospital Universitari Vall d´Hebron, Barcelona, Spain.
C Rodriguez-VigilPediatric Oncohaematology Unit, Paediatric Division, Hospital Universitario Miguel Servet, Zaragoza, Spain.
M I Benitez-CarbantePediatric Hematology and Oncology Division, Hospital Universitari Vall d´Hebron, Barcelona, Spain.
C Blazquez-GoñiHematology Division, Hospital Virgen del Rocío, Sevilla, Spain.
J A SalinasPediatric Division, Hospital Universitario SonEspases, Palma de Mallorca, Spain.
C Diaz-de-HerediaPediatric Hematology and Oncology Division, Hospital Universitari Vall d´Hebron, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Dyskeratosis congenita (DC) is a multisystem and ultra-rare hereditary disease characterized by somatic involvement, bone marrow failure, and predisposition to cancer. The main objective of this study is to describe the natural history of DC through a cohort of patients diagnosed in childhood and followed up for a long period of time. Material and methods: Multicenter, retrospective, longitudinal study conducted in patients followed up to 24 years since being diagnosed in childhood (between 1998 and 2020). Results: Fourteen patients were diagnosed with DC between the ages of 3 and 17 years (median, 8.5 years). They all had hematologic manifestations at diagnosis, and nine developed mucocutaneous manifestations during the first decade of life. Seven presented severe DC variants. All developed non-hematologic manifestations during follow-up. Mutations were identified in 12 patients. Thirteen progressed to bone marrow failure at a median age of 8 years [range, 3-18 years], and eight received a hematopoietic stem cell transplant. Median follow-up time was 9 years [range, 2-24 years]. Six patients died, the median age was 13 years [range, 6-24 years]. As of November 2022, eight patients were still alive, with a median age of 18 years [range, 6-32 years]. None of them have developed myeloblastic syndrome or cancer. Conclusions: DC was associated with high morbidity and mortality in our series. Hematologic manifestations appeared early and consistently. Non-hematologic manifestations developed progressively. No patient developed cancer possibly due to their young age. Due to the complexity of the disease multidisciplinary follow-up and adequate transition to adult care are essential.

Indexed as

aplastic anaemiadyskeratosis congenitahematopoeietic stem cell transplantationinherent bone marrow failuremultisystem diseasetelomeres

Identifiers

PMID37593443
PMCPMC10427857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.